Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) Equity Average (2019 - 2025)

Benitec Biopharma's Equity Average history spans 7 years, with the latest figure at $86.8 million for Q1 2025.

  • For Q1 2025, Equity Average rose 543.35% year-over-year to $86.8 million; the TTM value through Mar 2025 reached $86.8 million, up 543.35%, while the annual FY2024 figure was $23.7 million, 1438.59% up from the prior year.
  • Equity Average for Q1 2025 was $86.8 million at Benitec Biopharma, up from $70.1 million in the prior quarter.
  • Across five years, Equity Average topped out at $86.8 million in Q1 2025 and bottomed at $2.5 million in Q2 2023.
  • The 5-year median for Equity Average is $13.2 million (2021), against an average of $22.9 million.
  • The largest annual shift saw Equity Average plummeted 66.38% in 2022 before it skyrocketed 1095.28% in 2024.
  • A 5-year view of Equity Average shows it stood at $13.2 million in 2021, then fell by 10.28% to $11.8 million in 2022, then skyrocketed by 60.03% to $18.9 million in 2023, then skyrocketed by 270.91% to $70.1 million in 2024, then increased by 23.83% to $86.8 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Equity Average are $86.8 million (Q1 2025), $70.1 million (Q4 2024), and $55.7 million (Q3 2024).